Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

NCT ID: NCT06588504

Last Updated: 2025-12-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-10
• Study Completion Date: 2025-07-20

Brief Summary

This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D. This study wants to demonstrate that dasiglucagon can raise low blood sugar levels just as well as glucagon. Participants will get dasiglucagon and glucagon. In which treatment order participants get study medicines (dasiglucagon and glucagon) is decided by chance. Dasiglucagon is a new medicine, but doctors can prescribe it in the US as it is approved there. Doctors can prescribe glucagon in multiple countries including Japan as an approved medicine. The study will last for about 17 weeks. Participant cannot be in the study if the study doctor thinks that there are risks for participants health. Women cannot take part if pregnant, breast-feeding, plan to get pregnant, during the study period, or not using adequate contraceptive methods. For man: if participant have sex, participant and his partner must use an adequate birth control method during the study.

Conditions

Diabetes Mellitus, Type 1

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Adult Cohort: Dasiglucagon then Glucagon

Participants will receive a single subcutaneous (s.c.) injection of dasiglucagon in first dosing visit then a single intra-mascular (i.m.) injection of glucagon in next dosing visit.

Group Type: EXPERIMENTAL

Dasiglucagon

Intervention Type: DRUG

Participants will receive s.c. injection of dasiglucagon.

Adult Cohort: Glucagon then Dasiglucagon

Participants will receive a single i.m. injection of glucagon in first dosing visit then a single s.c. injection of dasiglucagon in next dosing visit.

Group Type: EXPERIMENTAL

Dasiglucagon

Intervention Type: DRUG

Participants will receive s.c. injection of dasiglucagon.

Glucagon

Intervention Type: DRUG

Participants will receive i.m. injection of glucagon.

Adolescent Cohort: Dasiglucagon

Participants will receive a single s.c. injection of dasiglucagon.

Group Type: EXPERIMENTAL

Dasiglucagon

Intervention Type: DRUG

Participants will receive s.c. injection of dasiglucagon.

Interventions

Dasiglucagon

Participants will receive s.c. injection of dasiglucagon.

Intervention Type: DRUG

Glucagon

Participants will receive i.m. injection of glucagon.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• For Adults: Asian male or female; For Adolescents: Japanese male or female.
• Age at the time of signing the informed consent:

For Adults: Age 18-75 years (both inclusive):

For Adolescents: Age 12-15 years (both inclusive).

• Diagnosed with T1D greater than (>)1 year before screening.
• Glycated haemoglobin (HbA1c) less than (<)10.0 percentage (%) (86 millimoles per mole [mmol/mol]) as assessed by subcontracted laboratory by the site on the day of screening.
• For adults: BMI between 18.5 and 29.9 kilogram per meter square (kg/m2) (both inclusive).

For adolescents: Body weight greater than or equal to (≥) 33.4 kilograms (kg).

• Treated with stable insulin treatment (based on the investigator's discretion preferably no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening.
• For Japanese participants: Japanese passport or equivalent For non-Japanese participants: Asian (non- Japanese passport or equivalent).

Exclusion Criteria

• Known or suspected hypersensitivity to study intervention(s) or related products (glucagon or its derivatives).
• Exposure to an investigational medicinal product (IMP) within 30 days or 5 times the half-life of the IMP (if known), whichever is longest before screening.
• Severe hypoglycaemia in the last month prior to screening.
• Hospitalisation for diabetic ketoacidosis (DKA) in the last month prior to screening.
• Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus).
• History of epilepsy or seizure disorder.
• Known presence or history of pheochromocytoma (i.e., adrenal gland tumour) or insulinoma (i.e., insulin-secreting pancreas tumour).
• Clinically significant abnormal electrocardiogram (ECG) at screening as evaluated by investigator.
• Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.

As declared by the participant or in the medical records.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novo Nordisk A/S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Transparency (dept. 2834)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Hakata Clinic

Fukuoka, , Japan

Countries

Japan

Other Identifiers

U1111-1300-1855

Identifier Type: OTHER

Identifier Source: secondary_id

jRCT2071240050

Identifier Type: REGISTRY

Identifier Source: secondary_id

NN9515-7675

Identifier Type: -

Identifier Source: org_study_id